NCT06393738 - A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Interventions

DRUG

ARV-393

Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles

Trial Locations (17)

2100

RECRUITING

Clinical Trial Site, Copenhagen

5000

RECRUITING

Clinical Trial Site, Odense C

8908

RECRUITING

Clinical Trial Site, Barcelona

10016

RECRUITING

Clinical Trial Site, New York

10021

RECRUITING

Clinical Trial Site, New York

10065

RECRUITING

Clinical Trial Site, New Brunswick

28050

RECRUITING

Clinical Trial Site, Madrid

30120

RECRUITING

Clinical Trial Site, El Palmar

31008

RECRUITING

Clinical Trial Site, Pamplona

37007

RECRUITING

Clinical Trial Site, Salamanca

37203

RECRUITING

Clinical Trial Site, Nashville

44122

RECRUITING

Clinical Trial Site, Cleveland

48201

RECRUITING

Clinical Trial Site, Detroit

77030

RECRUITING

Clinical Trial Site, Houston

06510

RECRUITING

Clinical Trial Site, New Haven

M5G 1Z5

RECRUITING

Clinical Trial Site, Toronto

H3T 1E2

RECRUITING

Clinical Trial Site, Montreal